APAC Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2031
The Asia-Pacific duchenne muscular dystrophy treatment market is expected to reach USD 1,215,876.64 thousand by 2030 from USD 331,133.48 thousand in 2022, growing at a CAGR of 18.2% in the forecast period of 2023 to 2030.
Market SegmentationAsia-Pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Duchenne Muscular Dystrophy Treatment Market Dynamics
Driver
• Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease
Restraint
• High treatment cost of DMD disorder
Opportunity
• Strategic initiatives by key market players
Market Players
Some of the key market players for Asia-Pacific duchenne muscular dystrophy treatment market are:
• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
• Capricor Therapeutics, Inc.
• Dyne Therapeutics
• BioMarin
• Stealth BioTherapeutics Inc
• Avidity Biosciences
• ReveraGen
• BioPharma, Inc.
• TAIHO PHARMACEUTICAL CO., LTD.
• Akashi RX
• ITALFARMACO S.p.
• NS Pharma, Inc.
• PTC Therapeutics.
• Pfizer Inc.
• FibroGen, Inc.
• SANTHERA PHARMACEUTICALS
• F. Hoffmann-La Roche Ltd